Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1961-1970 Newer>

HBS Working Knowledge April 25, 2005 Alfred D. Chandler	New Learning at American Home Products In the author's new history of the modern chemical and pharma industries, American Home Products follows a singular path to success. An excerpt from Shaping the Industrial Century.
The Motley Fool April 25, 2005 Charly Travers	Where Is QLT going? The drug maker's upcoming conference call needs to address the question. Shares are down 30% since the beginning of the year. Can QLT turn this around?
The Motley Fool April 25, 2005 Brian Gorman	Leaning on a Stronger Covance The drug development services company is helping big pharmaceutical firms. While the company's valuation of 24 times 2005 earnings is a bit a rich, Covance should be on investors' radar.
The Motley Fool April 22, 2005 Brian Gorman	Baxter Is on the Mend The medical products company continues to right itself for a brighter future. The firm's long-term positioning and diversified business may make it worth a closer look.
The Motley Fool April 22, 2005 Stephen D. Simpson	High-Test Growth Can the medical tester Biosite stay ahead of the competition and keep growth on track? A good quarter and a 50% increase in the stock over the past year not withstanding, diagnostics is often a tricky space for investors to find profits.
The Motley Fool April 22, 2005 Stephen D. Simpson	Success Is Intuitive Surgical robotics continues to grow, and Intuitive Surgical dominates the market. It's important to note, though, that valuation is a tricky matter when you're dealing with fast-growing companies that are basically pioneering entirely new businesses.
BusinessWeek May 2, 2005 Gene G. Marcial	What Other Biotechs See In Bioenvision Bioenvision's childhood leukemia drug Clofarabine has received FDA approval and is expected to increase the profitability of the drug maker.
InternetNews April 21, 2005 Tim Gray	HIPAA Deadline Passes Health care organizations still working to comply with privacy and security technology provisions of HIPAA.
The Motley Fool April 21, 2005 Stephen D. Simpson	Novartis' Triple Threat The Swiss drug giant boasts strong franchises in generics, cardiology, and oncology. It's hard not to think of Novartis as one of the highest-quality options in the pharmaceutical investing space.
The Motley Fool April 21, 2005 Stephen D. Simpson	SurModics' Profitable Ride The company is more of a biotech/pharmaceutical facilitator than a star, but that doesn't mean the profits are any less green. Investors need to approach the stock with their eyes fully open.
<Older 1961-1970 Newer> Return to current articles.